A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer

T. Ciuleanu, C. M. Tsai, C. J. Tsao, J. Milanowski, D. Amoroso, D. S. Heo, H. J.M. Groen, A. Szczesna, C. Y. Chung, T. Y. Chao, G. Middleton, A. Zeaiter, G. Klingelschmitt, B. Klughammer, N. Thatcher

Research output: Contribution to journal › Article › peer-review

33 Citations (Scopus)

Fingerprint

Dive into the research topics of 'A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science